Developmental and epileptic encephalopathy 89 is a rare genetic condition that affects early brain development and causes seizures. Many people with Developmental and epileptic encephalopathy 89 have seizures beginning in infancy and developmental delays that can range from mild to severe. It is lifelong, and features can vary by child and over time. Treatment focuses on seizure control with anti-seizure medicines and supportive therapies like physical, occupational, and speech therapy. The outlook depends on seizure control and developmental needs, and some children may face serious health complications.
Overview
Developmental and epileptic encephalopathy 89Symptoms
Developmental and epileptic encephalopathy 89 often begins in infancy with seizures, feeding difficulties, and low muscle tone. Many children have developmental delays, movement problems, and vision or hearing issues; early signs of developmental and epileptic encephalopathy 89 can be severe.
Outlook and prognosis
Many living with Developmental and epileptic encephalopathy 89 face ongoing seizures and developmental challenges, often beginning in infancy. Progress varies: some gain skills slowly with tailored therapies, while others remain significantly affected. Early, consistent care and seizure control support the best long-term function.
Causes and risk factors
Developmental and epileptic encephalopathy 89 is caused by a de novo change in a single gene. Rarely inherited; a parent with the variant or mosaicism raises recurrence risk. Illness, fever, or sleep loss don’t cause it but can worsen seizures.
Genetic influences
Genetics play a central role in Developmental and epileptic encephalopathy 89, with most cases caused by single-gene variants. These changes disrupt brain signaling, driving early seizures and developmental challenges. Genetic testing can confirm the cause, guide care, and inform family planning.
Diagnosis
Doctors assess early seizure patterns, developmental history, and neurologic exam, then review EEG and brain MRI findings. Genetic tests confirm the genetic diagnosis of Developmental and epileptic encephalopathy 89.
Treatment and drugs
Treatment for Developmental and epileptic encephalopathy 89 focuses on reducing seizures, supporting development, and improving day-to-day function. Care often combines anti-seizure medicines, rescue treatments, ketogenic diet, and therapies like physiotherapy, occupational, and speech therapy. Genetic counseling and coordinated neurology-led follow-up help adjust care over time.
Symptoms
Developmental and epileptic encephalopathy 89 can affect how a child develops, learns, and interacts from very early on. Families often first see seizures and delays in rolling, sitting, or babbling, which can change daily routines and care needs. Features vary from person to person and can change over time. Knowing the early features of Developmental and epileptic encephalopathy 89 can help you seek timely support and therapies.
Early on, this might look like brief staring spells, stiffening, or rhythmic jerks. Seizures can happen many times a day or in clusters, and often start in infancy. In Developmental and epileptic encephalopathy 89, seizures may be hard to control and can change over time.
Motor skills like holding the head, sitting, or walking tend to emerge later than expected. Learning and self-care often need ongoing therapies and extra practice. Some skills may remain limited despite consistent support.
First words may come late, and some children remain minimally verbal. Understanding may be stronger than talking, so gestures, signs, or devices can help communication. Many living with Developmental and epileptic encephalopathy 89 use alternative communication tools.
Low muscle tone (floppiness) in infancy can later shift to tight or stiff muscles. Clinicians call this hypotonia or spasticity, which means muscles don’t move as smoothly or easily. This can affect posture, comfort, and daily mobility.
How people usually first notice Developmental and epileptic encephalopathy 89?
Many families first notice something isn’t typical in the first months of life: a baby who’s unusually quiet or irritable, doesn’t make steady eye contact, or seems slow to reach early milestones like rolling or holding up the head. Seizures are often the clearest early clue in the first year—brief stiffening, sudden jerks, eye fluttering, or episodes that look like staring spells—and these prompt urgent medical evaluation; doctors may call this pattern “developmental and epileptic encephalopathy.” When people search for the first signs of Developmental and epileptic encephalopathy 89, they’re usually describing that mix of early developmental delays plus recurrent seizures that begin in infancy and quickly lead to more noticeable skill plateaus or regressions.
Types of Developmental and epileptic encephalopathy 89
Developmental and epileptic encephalopathy 89 (DEE89) is a rare genetic epilepsy syndrome caused by changes in a single gene, with symptoms that can vary in age at onset, seizure patterns, and developmental impact. People may notice different sets of symptoms depending on their situation. Clinicians often describe them in these categories: early-onset versus later-onset presentations, seizure-heavy versus development-focused courses, and milder versus more severe pathways. When people search for types of DEE89, they’re often asking about variants of DEE89 that track with these patterns, even though the underlying cause is the same gene.
Early-onset seizures
Seizures begin in the first months of life, often as brief staring spells, body stiffening, or clusters that happen many times a day. Developmental delays tend to appear early and may affect motor skills and speech. Some children also have low muscle tone and feeding difficulties.
Later-onset epilepsy
Seizures start in late infancy or early childhood, sometimes after a period of near-typical development. Learning or behavior challenges may surface gradually as seizures become more frequent. Motor milestones may be delayed but can still progress with therapy.
Seizure-predominant course
Frequent or hard-to-control seizures are the main feature, with multiple seizure types over time. Development may plateau or slow during periods of intense seizure activity. Better seizure control can sometimes lead to gains in skills.
Development-predominant course
Seizures are less frequent or respond to treatment, but developmental differences in language, learning, or coordination stand out. Day-to-day challenges may center on communication and fine motor tasks. Therapies and structured supports often help skills grow.
Milder pathway
Symptoms are present but less intense, with seizures that may respond to medication and gradual developmental progress. Children may attend mainstream settings with extra support. Even within the milder range, needs can change as school demands increase.
Severe pathway
Seizures are frequent, may resist several medications, and can include prolonged events. Developmental impairment is more marked, and some children need assistance with mobility, communication, and daily care. Care teams often include neurology, rehabilitation, and nutrition.
What genetics can tell you about symptoms
Some people with developmental and epileptic encephalopathy 89 (DEE89) have variants in the PPP3CA gene that disrupt brain signaling, leading to early-onset seizures, severe developmental delays, low muscle tone, and feeding or breathing problems. Certain variants cluster in key protein regions, and those spots often correlate with more frequent seizures, movement issues, and limited speech.
Causes and risk factors
Developmental and epileptic encephalopathy 89 is most often caused by a new change in a single gene that affects brain development. This change usually happens by chance and is not inherited from either parent. In a small number of families, the change can be inherited, so genetic counseling can clarify family risk before early symptoms of Developmental and epileptic encephalopathy 89 appear. Doctors distinguish between risk factors you can change and those you can’t. While genes drive the condition, fever, sleep loss, illness, or missed medicines can worsen seizures, and steady routines and prompt care during infections may help reduce triggers.
Environmental and biological risk factors
Developmental and epileptic encephalopathy 89 usually arises from new changes that happen before or at conception. This section highlights environmental and biological risk factors that can increase the chance of those changes. Doctors often group risks into internal (biological) and external (environmental). These do not guarantee a condition will occur, but they can help frame environmental risk factors for Developmental and epileptic encephalopathy 89.
As men age, more cell divisions in the testes can lead to new DNA changes in sperm. This slightly raises the chance of conditions like Developmental and epileptic encephalopathy 89 arising spontaneously. The increase grows gradually with age.
Aging eggs are more prone to errors when cells divide. This may slightly increase the chance of new changes linked to Developmental and epileptic encephalopathy 89. The effect is generally smaller than the paternal-age effect for single-gene changes.
High-dose ionizing radiation to the ovaries or testes can damage DNA in sperm or egg cells. This can raise the chance of new DNA changes in a future pregnancy. Medical teams often recommend waiting after high exposures before trying to conceive.
Some cancer medicines are mutagenic and can injure eggs or sperm. Conception too soon after treatment may carry a higher chance of new DNA changes. Clinicians may suggest a recovery period before pregnancy.
Genetic risk factors
Most cases of Developmental and epileptic encephalopathy 89 (DEE89) come from a change in a single gene that affects how brain cells signal. These changes are often new (de novo), meaning they arise in the egg, sperm, or very early embryo and aren’t inherited from either parent. Understanding the genetic causes of Developmental and epileptic encephalopathy 89 can clarify family risk across pregnancies. Risk is not destiny—it varies widely between individuals.
New gene change: A variant starts for the first time in the child (de novo) rather than being passed down. This is a common genetic cause of Developmental and epileptic encephalopathy 89. Nothing parents did or didn’t do triggers this change.
Inherited from parent: A parent who carries the gene change can pass it to a child. The parent may have mild or no features, so the family history can look limited. Each pregnancy has a chance to inherit the change.
Parental germline mosaicism: A gene change may exist only in some of a parent’s egg or sperm cells (mosaicism). This can raise the chance of another child with Developmental and epileptic encephalopathy 89 even if routine blood testing in the parent is negative.
Gene deletions/duplications: A small piece of the gene may be missing or extra (a deletion or duplication). These dosage changes can disrupt normal brain signaling and lead to DEE89. They may occur de novo or be inherited.
Chromosome rearrangement carrier: A parent with a balanced chromosomal swap near the relevant gene can be healthy but face a higher chance of a child with Developmental and epileptic encephalopathy 89. In offspring, the swap can break or misplace the gene and cause disease.
Variable effects: People with the same gene change can have different seizure patterns and developmental outcomes. Differences in other genes may act like dimmer switches that raise or lower impact. This helps explain why severity varies within some families.
Lifestyle risk factors
Developmental and epileptic encephalopathy 89 is a genetic condition; lifestyle habits do not cause it, but day-to-day choices can influence seizure control, developmental participation, and complication risks. Care routines that stabilize sleep, nutrition, and medication timing can reduce avoidable seizure triggers. The points below focus on how lifestyle affects Developmental and epileptic encephalopathy 89 in practical ways for patients and caregivers. These are not cures, but levers that may lessen seizure burden or improve function.
Irregular or short sleep can lower seizure threshold and worsen daytime irritability or cognitive fatigue. A consistent sleep schedule and bedtime routine may reduce seizure clustering and improve alertness.
Late or missed doses can precipitate breakthrough seizures and status epilepticus. Tools like alarms, pill organizers, and caregiver double-checks help keep levels steady.
Viral illnesses and fever commonly trigger more seizures and regression in skills. Early fever control and hydration during sickness may blunt seizure escalation.
Dehydration or electrolyte swings can provoke seizures and sluggish recovery after events. Steady fluid intake and prompt replacement during heat or illness support stability.
Risk prevention
Developmental and epileptic encephalopathy 89 is a genetic condition, so there’s no way to prevent the condition itself. Prevention focuses on lowering seizure frequency, avoiding complications, and keeping day‑to‑day health as stable as possible. Recognizing early symptoms of Developmental and epileptic encephalopathy 89 can speed diagnosis and help families get support sooner. Even if you can’t remove all risks, prevention can reduce their impact.
If DEE89 is confirmed in your family, a genetic counselor can explain inheritance and testing options. Some families consider carrier testing, IVF with embryo testing, or prenatal testing for future pregnancies.
Discuss family‑planning choices early if DEE89 runs in your family. Pre‑pregnancy counseling can clarify risks and the pros and cons of each reproductive option.
Taking anti‑seizure medicines exactly as prescribed lowers breakthrough seizures. Set reminders and plan for refills to avoid missed doses.
Regular sleep and good hydration can reduce seizure triggers in DEE89. If flashing lights or screen patterns seem to provoke events, limit exposure and discuss this with your neurologist.
Transmission
Developmental and epileptic encephalopathy 89 is a genetic condition and isn’t contagious. In many children, it’s caused by a new (de novo) change in a single gene that happens for the first time in the egg, sperm, or very early development, so parents typically don’t have the same change. If a parent does carry the gene change, it can be passed to children, but the chance depends on the exact gene and test results; a genetics professional can explain how Developmental and epileptic encephalopathy 89 is inherited in your family. Rarely, a parent may have the change only in some egg or sperm cells (germline mosaicism), which makes the chance of it happening again low but not zero.
When to test your genes
Consider genetic testing if seizures begin early, are hard to control, or come with developmental delays or regression, especially in infancy. Testing is also appropriate when brain MRI or EEG lacks a clear cause, there’s a family history of epilepsy or unexplained childhood deaths, or standard treatments fail. Results can guide medication choices, prognosis, and eligibility for clinical trials or supportive services.
Diagnosis
Many families first seek answers after seizures begin in infancy or early childhood and development doesn’t follow the expected pace. The genetic diagnosis of Developmental and epileptic encephalopathy 89 usually combines what doctors see in the clinic with confirmatory lab tests. Early and accurate diagnosis can help you plan ahead with confidence. Testing also helps clarify prognosis and guide treatment options and family planning.
Clinicians look for early-onset seizures, delays in milestones like sitting or speaking, and changes in muscle tone. These clinical features raise suspicion for Developmental and epileptic encephalopathy 89 and guide which tests to order.
Providers review when skills emerged or stalled, and whether there was any loss of abilities. A clear timeline helps separate DEE89 from other causes of seizures and delay.
An electroencephalogram records brain wave patterns and can show seizure activity between events. Certain patterns support an epileptic encephalopathy, even if seizures are brief or hard to witness.
Imaging checks for structural brain differences that could explain seizures. MRI may be normal or show nonspecific changes, but it helps rule out other conditions before confirming Developmental and epileptic encephalopathy 89.
Stages of Developmental and epileptic encephalopathy 89
Developmental and epileptic encephalopathy 89 does not have defined progression stages. This condition tends to vary from child to child, with seizures and developmental needs changing over time rather than following a predictable, step-by-step path. Different tests may be suggested to help confirm the cause and guide care, including an EEG, brain imaging, and genetic testing. Doctors usually focus on the story of early symptoms of Developmental and epileptic encephalopathy 89—such as early-onset seizures and developmental delays—along with ongoing checks of growth, learning, and seizure patterns to track changes and adjust treatment.
Outlook and prognosis
Living with Developmental and epileptic encephalopathy 89 can affect daily routines in many ways, from interrupted sleep due to night-time seizures to delays in speech, movement, or learning that change how school or therapy plans are set up. The outlook is not the same for everyone, but improvements in seizure control, nutrition, and respiratory support have helped many children live longer and with better comfort. Some children have seizures that are hard to control and developmental challenges that range from moderate to severe, while others may see periods where seizures ease or skills slowly build with therapy.
Prognosis refers to how a condition tends to change or stabilize over time. In DEE89, lifelong neurologic disability is common, and seizures often begin early, which can affect brain development and day-to-day independence. Early symptoms of Developmental and epileptic encephalopathy 89 usually include frequent seizures and delayed milestones; getting care quickly can help reduce complications like injuries from falls, feeding difficulties, and breathing problems. Serious complications—such as pneumonia from swallowing issues or prolonged seizures—can be life-threatening, and some children do face shortened life expectancy, particularly when seizures remain uncontrolled or when there are ongoing breathing problems.
Over time, most people with DEE89 need ongoing, team-based care that may include anti-seizure medicines, dietary therapies, and supportive equipment for mobility, feeding, or communication. With ongoing care, many people maintain better seizure control and comfort, though most will require significant assistance with daily activities throughout life. Genetic testing can sometimes provide more insight into prognosis, since specific gene changes and their effects can guide expectations and treatment choices. Talk with your doctor about what your personal outlook might look like, and ask how your child’s seizure pattern, feeding, breathing, sleep, and growth trends shape the long-term picture.
Long-term effects
Developmental and epileptic encephalopathy 89 often has lifelong effects that begin early and evolve over time. Long-term effects vary widely, and the course can look different from one child to another. Families often recall early symptoms of Developmental and epileptic encephalopathy 89 appearing in infancy, with effects that continue over time. Doctors often describe these as long-term effects or chronic outcomes.
Seizures often continue beyond early childhood, though patterns may change. Some periods are quieter, while others bring more frequent events.
Learning and thinking skills may be delayed from early on and remain affected. Many need long-term educational and daily living support.
Muscle tone can be low or stiff, affecting posture and movement. Balance and coordination often remain limited into later childhood and adulthood.
Speech may be very limited or absent for some with Developmental and epileptic encephalopathy 89. Many rely on nonverbal signals or assistive methods to communicate.
How is it to live with Developmental and epileptic encephalopathy 89?
Living with developmental and epileptic encephalopathy 89 often means navigating frequent seizures, developmental delays, and fluctuating energy and attention from day to day, with medical appointments and therapies shaping much of the routine. Many families build schedules around medication timing, seizure safety, and communication supports, while celebrating small gains that come with consistent therapies. For siblings, caregivers, and classmates, it can bring extra responsibility and learning—adapting play, being alert to seizure signs, and finding inclusive ways to connect. With coordinated care, accessible schooling, and community support, many families find a steady rhythm that balances safety, comfort, and moments of joy.
Treatment and drugs
Treatment for Developmental and epileptic encephalopathy 89 (DEE89) focuses on reducing seizures, supporting development, and improving day‑to‑day function. Doctors sometimes recommend a combination of lifestyle changes and drugs, often starting with anti‑seizure medicines such as levetiracetam, valproate, topiramate, clobazam, or others; if seizures remain frequent, options like the ketogenic diet, vagus nerve stimulation, or combination therapy may be considered. Because DEE89 can affect movement, learning, speech, and behavior, many people benefit from early and ongoing therapies, including physical, occupational, and speech therapy, with tailored educational support. Genetic counseling can help families understand the condition and whether clinical trials or gene‑informed treatments may be available in the future. Keep track of how you feel, and share this with your care team, since treatment plans for DEE89 often need careful adjustments over time to balance seizure control with side effects.
Non-drug treatment
Daily life with Developmental and epileptic encephalopathy 89 can involve seizures, delays in motor and communication skills, feeding challenges, and sleep disruption, so care often extends well beyond medicines. Beyond prescriptions, supportive therapies can help families build routines that reduce risks and support development. Starting early matters—early symptoms of Developmental and epileptic encephalopathy 89 may prompt referrals to therapy services that can shape milestones over time. Plans are tailored, reviewed often, and adjusted as needs change.
A high-fat, very low-carbohydrate medical diet can reduce seizure frequency for some. It requires careful planning, monitoring, and support from a dietitian and medical team.
Targeted exercises help with head control, posture, and movement patterns. This can reduce stiffness or low muscle tone and ease daily care tasks.
Skills-based sessions focus on hand use, positioning, and daily activities like dressing or feeding. Therapists can adapt tools and routines to fit Developmental and epileptic encephalopathy 89 needs at home and school.
Therapy builds early communication, feeding, and swallowing skills. For many living with Developmental and epileptic encephalopathy 89, therapists also introduce alternative communication methods to express needs.
Your genes may have an impact on how drugs work for you
Medicines for developmental and epileptic encephalopathy 89 can work differently depending on the specific gene change, affecting how seizures respond and which side effects appear. Genetic results can guide doctors toward drugs more likely to help and away from those that may worsen seizures.
Pharmacological treatments
Medicines aim to reduce seizures, protect learning and comfort, and simplify daily routines for families. Treatment in developmental and epileptic encephalopathy 89 (DEE89) is individualized, because seizure patterns and responses can differ. Sometimes medicines are taken short-term (acute treatment), while others are used long-term (maintenance therapy). These drugs do not change early symptoms of developmental and epileptic encephalopathy 89, but better seizure control may make day-to-day care easier.
Often used first because it works across many seizure types and is generally well tolerated. Irritability or sleep changes can occur. It can be combined with other medicines in DEE89.
Broad-spectrum control for generalized and focal seizures. Doctors monitor liver health and platelets, and avoid in pregnancy due to birth defect risk. It can be helpful for mixed seizure types in DEE89.
A calming benzodiazepine that reduces seizure bursts and clusters. Sleepiness and drooling can happen, and tolerance may develop over time. It is often added when first-line drugs are not enough.
Can help generalized and focal seizures and may brighten alertness for some. It must be increased slowly to lower the risk of rash. It is frequently paired with valproate or levetiracetam in DEE89.
Genetic influences
For most families, Developmental and epileptic encephalopathy 89 (DEE89) is driven by a change in a single gene rather than anything parents did during pregnancy. In many children, this gene change arises for the first time in them, so there may be no previous family history. Less often, the change is inherited from a parent; the exact pattern of inheritance depends on which gene is involved. DNA testing can sometimes identify these changes. Finding the exact gene can clarify the genetic causes of Developmental and epileptic encephalopathy 89, help tailor care, and inform the chance of it happening again in a future pregnancy. When parents test negative on a blood test, the chance of recurrence is usually low, though a small risk can remain if the change is present in a tiny fraction of a parent’s eggs or sperm. Because different genes can lead to a similar picture—and the same gene change can affect children in different ways—genetic counseling can help you understand what a result means for your family.
Is Developmental and epileptic encephalopathy 89 genetic?
Genetics play a central role in Developmental and epileptic encephalopathy 89, with most cases caused by single-gene variants. These changes disrupt brain signaling, driving early seizures and developmental challenges. Genetic testing can confirm the cause, guide care, and inform family planning.
Pharmacogenetics—how genetics influence drug effects
Choosing medicines isn’t one-size-fits-all, and the gene change behind the seizures can shape which options are most promising and safest. Alongside medical history and seizure patterns, genetic testing can help tailor medicine choices and doses. In Developmental and epileptic encephalopathy 89, the specific variant can hint at which drug classes may help—or occasionally make seizures worse—such as medicines that act on sodium channels versus those that boost the brain’s calming GABA signals. Separate from the disease gene, pharmacogenetic markers can guide safety and dosing: HLA-B*15:02 or HLA-A*31:01 raises the risk of serious skin reactions with carbamazepine or oxcarbazepine, CYP2C9 influences phenytoin dosing, and CYP2C19 can change how someone responds to clobazam. If testing shows certain mitochondrial gene changes like POLG, doctors usually avoid valproate because of a higher risk of liver problems. Taken together, these results help narrow the best treatment approach for Developmental and epileptic encephalopathy 89 and may reduce trial-and-error.
Interactions with other conditions
Day to day, infections, fever, or even poor sleep can make seizures spike and recovery feel slower for people living with Developmental and epileptic encephalopathy 89 (DEE89). Doctors call it a “comorbidity” when two conditions occur together. Feeding difficulties, reflux, and constipation are common in DEE89 and can affect how well seizure medicines are absorbed, while reflux and swallowing problems may raise the risk of chest infections that, in turn, can trigger more seizures. Sleep disorders, including sleep apnea, can also worsen seizure control; likewise, spine curvature or muscle stiffness may limit lung function and make breathing illnesses harder to shake. Some children with DEE89 have autistic features or vision and hearing differences, which can overlap with early symptoms of Developmental and epileptic encephalopathy 89 and make communication and learning needs more complex. Interactions can look very different from person to person, so coordinating care across neurology, gastroenterology, rehabilitation, and primary care—and checking for drug–drug interactions when new medicines are added—can help keep seizures and overall health steadier.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described infants who developed normally at first, then began having frequent seizures and lost skills they had just gained. Families told of nights broken by sudden convulsions and days when a baby who had been smiling and reaching stopped making eye contact. These early accounts mirror what many families facing Developmental and epileptic encephalopathy 89 experience today: seizures starting in infancy alongside slowing or regression in development.
First described in the medical literature as severe infant-onset epilepsy with developmental decline, the condition was initially grouped with broader “early epileptic encephalopathies.” Doctors focused on what they could see—hard‑to‑control seizures, low muscle tone, feeding difficulties—because the root cause was unknown. Over time, descriptions became more precise as clinicians noticed patterns: onset in the first year of life, multiple seizure types, and developmental challenges that ranged from mild delays to profound disability.
Advances in genetics changed the picture. In recent decades, knowledge has built on a long tradition of observation. Researchers studying families with similar histories found that some children shared changes in the same gene, often involved in brain signaling. As gene testing became more widely available, what was once thought to be a single broad syndrome was divided into several related conditions, including Developmental and epileptic encephalopathy 89. This shift helped explain why two children with similar seizures could have different long‑term needs and responses to treatment.
Medical classifications changed as the field recognized that seizure patterns and development are linked to the underlying gene. Instead of labeling all early, severe epilepsies the same way, specialists began numbering and naming them based on the gene involved. That’s how DEE89 came to be recognized as its own entry within the developmental and epileptic encephalopathies. Not every early description was complete, yet together they built the foundation of today’s knowledge.
With each decade, the timeline has moved earlier. What once required years of observation can now be clarified in infancy with genetic testing, allowing families and clinicians to plan therapies sooner. Still, history reminds us that the condition is variable. Some children with Developmental and epileptic encephalopathy 89 have daily seizures; others have fewer but still need significant developmental support. Awareness of past misunderstandings can guide better, more individualized care now, while ongoing research continues to refine how we define, diagnose, and manage DEE89.